Thinking of joining a study?

Register your interest

Become a volunteer?

NCT06353191 | RECRUITING | Hematopoietic and Lymphatic System Neoplasm

Biomarkers to Predict Cancer Therapy-related Cardiotoxicity
Sponsor:

Mayo Clinic

Brief Summary:

This study evaluates why some cancer patients but not others experience changes in heart function following treatment with chemotherapy.

Condition or disease

Hematopoietic and Lymphatic System Neoplasm

Malignant Solid Neoplasm

Intervention/treatment

Non-Interventional Study

Detailed Description:

PRIMARY OBJECTIVE: I. To collect biospecimens from 1) patients who developed chemotherapy related cardiac toxicity (CRCT) and 2) patients who are at a high risk for developing CRCT. OUTLINE: This is an observational study. Patients undergo blood sample collection and have their medical records reviewed on study.

Study Type : OBSERVATIONAL
Estimated Enrollment : 1000 participants
Official Title : Biomarkers to Predict Cancer Therapy-Related Cardiotoxicity
Actual Study Start Date : 2019-05-03
Estimated Primary Completion Date : 2026-06-01
Estimated Study Completion Date : 2026-06-01

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • * 18 years of age or older
  • * Treated for any malignancy with any type of chemotherapy including oral, parenteral therapy and immunotherapy
  • * One of the following
    • * Diagnosed with cardiotoxicity defined as; cardiomyopathy, symptomatic heart failure, asymptomatic reduced systolic function, acute coronary syndrome, myocardial infarction, critical limb ischemia, cardiac arrhythmias or myocarditis possibly related to prior cancer treatment
    • * Completed chemotherapy with no cardiotoxicity at least two years post treatment
    • * Patients with cancer who will be initiating systemic therapy with potentially cardiotoxic medications. This will include chemotherapy, immunotherapy, targeted therapy that have been associated with cardiac toxicity
    • * An understanding of the protocol and its requirements, risks, and discomforts
    • * The ability and willingness to sign an informed consent
    Exclusion Criteria
    • - Inability on the part of the patient to understand the informed consent or be compliant with the protocol
Biomarkers to Predict Cancer Therapy-related Cardiotoxicity

Location Details

NCT06353191

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

RECRUITING

United States, Arizona

Mayo Clinic in Arizona

Scottsdale, Arizona, United States, 85259

RECRUITING

United States, Florida

Mayo Clinic in Florida

Jacksonville, Florida, United States, 32224-9980

RECRUITING

United States, Florida

Moffitt Cancer Center

Tampa, Florida, United States, 33612

SUSPENDED

United States, Minnesota

Mayo Clinic in Rochester

Rochester, Minnesota, United States, 55905